Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies (Q38971627)

8 September 2017

Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies (English)

1 reference

8 September 2017

Experimental Treatments for Leptomeningeal Metastases from Solid Malignancies (English)

0 references

author

Keiran S M Smalley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Solmaz Sahebjam

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Peter A Forsyth

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Nam D Tran

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

1 January 2017

1 reference

8 September 2017

January 2017

0 references

published in

Cancer Control

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

42-46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Vemurafenib for leptomeningeal melanomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Beneath the blood brain barrier: the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Predictors of tumor-infiltrating lymphocyte efficacy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481702400106

10.1177/107327481702400106

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28178711%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference